News & Videos - SPRING BANK PHARMACEUTICALS

F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals To Commence Trading November 23 on Nasdaq: FSTX PR Newswire CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 CAMBRIDGE, England and CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020 ) a clinical-stage immuno-oncology company determined to transform the lives of patients with cancer through the development of innovative tetravalent mAb 2 bispecific...

CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics 1-for-4 Reverse Stock Split to be Effective November 23, 2020 PR Newswire HOPKINTON, Mass., Nov. 20, 2020 HOPKINTON, Mass. , Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release reads: HOPKINTON, MA , Nov. 19, 2020 – Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH)...

HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier today, Spring Bank’s stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Limited (“F-star”) in connection with its...

HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock,...

HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. SB 11285 is Spring Bank’s intravenously (IV)-administered STING agonist...

Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in connection with its merger with F-star Therapeutics Limited. The lawsuit seeks damages and/or equitable relief on behalf of Spring Bank shareholders under the federal securities laws. If you are a Spring Bank shareholder and would like to join the action, visit Spring Bank Class Action or contact Daniel Sadeh or Zachary...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Spring Bank Pharmaceuticals, Inc. PR Newswire NEW YORK, Sept. 22, 2020 NEW YORK , Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and exchange agreement with privately-held biopharmaceutical company, F-star Therapeutics Limited...

NEW YORK, NY / ACCESSWIRE / September 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) Agreement Announcement: July 29, 2020 Transaction Details: "). Under the terms of the merger, Spring Bank will issue shares of common stock to the owners of F-Star, with current holders of Spring Bank...

NEW YORK, NY / ACCESWIRE / September 17, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) Agreement Announcement: July 29, 2020 Transaction Details: "). Under the terms of the merger, Spring Bank will issue shares of common stock to the owners of F-Star, with current holders of Spring Bank...

Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Jernigan Capital, Inc., Momenta Pharmaceuticals, Inc., NTN Buzztime, Inc., Principia Biopharma Inc., Spring Bank Pharmaceuticals, Inc., Varian Medical Systems, Inc., and Yintech Investment Holdings Limited PR Newswire NEW YORK, Aug. 26, 2020 NEW YORK , Aug. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc. (NASDAQ: CGIX) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection...

Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs Continued to advance IV SB 11285 clinical trial to additional monotherapy and combination dosing cohorts Abstracts for IV SB 11285 accepted by major oncology scientific conferences for presentation in Q3 and Q4 2020 HOPKINTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical...

SPRING BANK PARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Spring Bank Pharmaceuticals, Inc. - SBPH PR Newswire NEW ORLEANS, Aug. 6, 2020 NEW ORLEANS , Aug. 6, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Spring Bank Pharmaceuticals, Inc. (NasdaqGS: SBPH) ("the Company") with F-star...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spring Bank Pharmaceuticals, Inc. - SBPH PR Newswire NEW YORK, Aug. 5, 2020 NEW YORK , Aug. 5, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (Nasdaq: SBPH) relating to its agreement to acquire F-star...

Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed merger of the company with F-star Therapeutics, Limited. Spring Bank Pharmaceuticals stockholders will own approximately 38.8% of the combined company. The transaction is expected to close in late 2020. If you are a stockholder of Spring Bank Pharmaceuticals, Inc. and are interested in obtaining additional information...

Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programs Combined company expected to have at least $40 million in cash prior to closing Spring Bank stockholders to receive two separate contingent value rights related to Spring Bank’s STING agonist and STING antagonist programs Companies to host joint conference call on July 30, 2020 at 7:30 a.m. Eastern Time HOPKINTON, Mass. and CAMBRIDGE, United Kingdom and CAMBRIDGE,...

- Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) - Clinical Poster for IV SB 11285 Phase 1a/1b trial presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting HOPKINTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a...

HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be participating in the Jefferies Virtual Global Healthcare Conference, taking place June 2-4, 2020. Martin Driscoll, Spring Bank’s President and CEO, will be providing a corporate presentation on June 2, 2020...

HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced that a trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be...

Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche’s Tecentriq ® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I and STING agonists portfolio as potential therapeutics and/or vaccine adjuvants for COVID-19 HOPKINTON, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain...

Pursuing collaborations to develop internal compounds for potential treatment of COVID-19 Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient dosed in next cohort Clinical abstracts for IV SB 11285 Phase 1a/1b trial accepted for presentation at ASCO and 7 th ImmunoTherapy of Cancer Conferences HOPKINTON, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage...